Effects of the ACTH4-9 analog Org2766 on brain plasticity: modulation of excitatory neurotransmission?

Social stress and corticosterone regionally upregulate limbic N-methyl-d-aspartatereceptor (NR) subunit type NR2A and NR2B in the lizard anolis carolinensis

Social aggression in the lizard Anolis carolinensis produces dominant and subordinate relationships while elevating corticosterone levels and monoaminergic transmitter activity in hippocampus (medial and mediodorsal cortex). Adaptive social behavior for dominant and subordinate male A. carolinensis is learned during aggressive interaction and therefore was hypothesized to involve hippocampus and regulation of N-methyl-d-aspartate (NMDA) receptors. To test the effects of social stress and corticosterone on NMDA receptor subunits (NR), male lizards were either paired or given two injections of corticosterone 1 day apart. Paired males were allowed to form dominant-subordinate relationships and were killed 1 day later. Groups included isolated controls, dominant males, subordinate males and males injected with corticosterone. Brains were processed for glutamate receptor subunit immunohistochemistry and fluorescence was analyzed by image analysis for NR(2A) and NR(2B) in the small and large cell divisions of the medial and mediodorsal cortex. In the small granule cell division there were no significant differences in NR(2A) or NR(2B) immunoreactivity among all groups. In contrast, there was a significant upregulation of NR(2A) and NR(2B) subunits in the large pyramidal cell division in all three experimental groups as compared with controls. The results revealed significantly increased NR(2A) and NR(2B) subunits in behaving animals, whereas animals simply injected with corticosterone showed less of an effect, although they were significantly increased over control. Upregulation of NR(2) subunits occurs during stressful social interactions and is likely to be regulated in part by glucocorticoids. The data also suggest that learning social roles during stressful aggressive interactions may involve NMDA receptor-mediated mechanisms.

Postnatal treatment with ACTH-(4-9) analog ORG 2766 attenuates N-methyl-D-aspartate-induced excitotoxicity in rat nucleus basalis in adulthood

It has been reported that the ACTH-(4-9) analog H-Met(O(2))-Glu-His-Phe-D-Lys-Phe-OH (ORG 2766) administered in adulthood has trophic effects on neuronal tissue and when given postnatally, it can induce long-lasting changes in brain development. In the present study, we investigated whether early postnatal treatment with ORG 2766 affects adult neuronal vulnerability, i.e. the sensitivity of cholinergic neurons against excitotoxic damage. Wistar rat pups received injections of ORG 2766 or saline on postnatal days 1, 3 and 5 and were then left undisturbed until adulthood. At the age of 6 months, the animals were subjected to unilateral lesion of magnocellular basal nucleus by infusion of high dose of N-methyl-D-aspartate (NMDA). The effects of the excitotoxic insult were studied 28 hours and 12 days after the lesion by measuring both the acute cholinergic and glial responses, and the final outcome of the degeneration process. Twenty eight hours after NMDA infusion, postnatally ACTH-(4-9)-treated animals showed stronger suppression of choline-acetyltransferase immunoreactivity and increased reaction of glial fibrillary acidic protein -immunopositive astrocytes in the lesioned nucleus compared to control animals. However, 12 days post-surgery, the NMDA-induced loss of cholinergic neurons, as well as the decrease of their acetylcholinesterase -positive fibre projections in the cortex, were less in ACTH-(4-9) animals. Our data indicate that the early developmental effects of ACTH-(4-9) influence intrinsic neuroprotective mechanisms and reactivity of neuronal and glial cells, thereby resulting in a facilitated rescuing mechanism following excitotoxic injury.

Neurotrophic ACTH4-9 analogue therapy normalizes electroencephalographic alterations in chronic experimental allergic encephalomyelitis

Chronic experimental allergic encephalomyelitis (CEAE) is an established experimental model for multiple sclerosis (MS). The demyelinating lesions in the white matter of the central nervous system observed in CEAE and in MS are accompanied by various neurophysiological alterations. Among the best defined electrophysiological abnormalities are the changes in event-related potentials, in particular evoked potentials involving the spinal cord, i.e. motor and sensory evoked potentials. Less familiar are the changes observed in the electroencephalogram of CEAE-affected animals, which are also encountered in the human equivalent, MS. In the present experiment we evaluated the therapeutic value of a neurotrophic peptide treatment [H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH, an ACTH4-9 analogue] and its effect on the delayed flash visual evoked potentials (VEP) and power spectra of the electroencephalogram, during a 17-week follow-up of CEAE. CEAE animals treated with the neurotrophic peptide were protected against the development of neurological symptoms during the course of the demyelinating syndrome. VEPs of animals suffering from CEAE showed a delay of the latencies of the late components which was significantly counteracted by peptide treatment. The peak-to-peak amplitude of the VEP afterdischarge recorded from CEAE animals was significantly increased during the course of CEAE and correlated closely with the progression of the myelinopathy. Furthermore, CEAE animals showed an increase of electroencephalogram (EEG) beta activity of up to 500% as compared with the age-matched control group. This increase in beta power mainly consisted of a prevailing 20-21 Hz peak, a frequency that normally is not dominant in control EEG recordings of the rat during passive wakefulness. All these electrophysiological phenomena were absent in ACTH4-9 analogue-treated animals. The present findings underscore the potential importance of a neurotrophic peptide treatment in the pharmacotherapy of central demyelinating syndromes, and possibly of MS.

The effect of the adrenocortical axis upon recovery from closed head injury

Fragments and analogs of the hormone ACTH were previously shown to have beneficial effect on the outcome of head injury, while elevated levels of corticosterone (CS) exacerbate it. In the present study we investigated the role of the hypothalamo-pituitary-adrenal (HPA) axis in the pathophysiology of closed head injury (CHI). CHI was produced in ether-anesthetized rats by a calibrated weight-drop device. After evaluating the functional status according to a set of criteria, at 1 and 24 h, the rats were sacrificed and cortical tissue was removed to determine its water content. CHI was also produced in rats that underwent surgical procedures to remove their adrenal gland (ADEX) or the pituitary (HypoX), thus altering the levels of their circulating HPA hormones. Given after CHI, to rats with intact HPA axis, ACTH reduced edema and improved recovery. ADEX rats (6 days postsurgery) had 10-fold higher levels of plasma ACTH. ADEX rats subjected to CHI showed improved functional outcome (p = 0.008) and reduced edema (p = 0.02). We then produced CHI in three groups of rats: HypoX (15 days postsurgery), HypoX treated with ACTH, and controls. In HypoX rats, CHI resulted in increased mortality (35% vs 0) and edema in the surviving rats, and a slower recovery, as compared with the control. Mortality was prevented, edema slightly reduced, and recovery significantly improved after administration of 1-24-ACTH to HypoX rats with CHI. Our results suggest that ACTH has a cerebroprotective effect on the outcome of CHI.

ACTH-related peptides: receptors and signal transduction systems involved in their neurotrophic and neuroprotective actions

ACTH-related peptides are promising neurotrophic and neuroprotective agents, as demonstrated in many in vivo and in vitro studies. They accelerate nerve repair after injury, improving both sensor and motor function. Furthermore, ACTH-related peptides have neuroprotective properties against cisplatin- and taxol-induced neurotoxicity, they improve neuronal function in animals with neuropathy due to experimental diabetes, and they prevent degeneration of myelinated axons in rats suffering from experimental allergic neuritis, a model of peripheral demyelinating neuropathy. Studies in neuronal cultures have corroborated these clinical observations and serve to investigate the mechanism of action of the ACTH-related peptide effects. This paper reviews both in vitro and in vivo effects and emphasizes the mechanism of action. Recent data on melanotrophic receptors and signal transduction systems will be discussed in this context.

Melanocortins as factors in somatic neuromuscular growth and regrowth

Melanocortins, non-corticotropic fragments of adrenocorticotropic hormone, accelerate growth of the developing neuromuscular system and regrowth of damaged neurons, both in the adult and neonatal rat. Morphological, electrophysiological and behavioral characteristics are all improved by melanocortins, which, however, vary in potency, with alpha-MSH being the most effective. Tissue substrate, dosage, critical time periods and pattern of neuropeptide administration are all important variables. Melanocortins protect central neurons affecting motor behavior during development or following neuronal damage in the adult brain. Possible mechanisms of melanocortin action are discussed.

Influence of ifenprodil on the ACTH-induced behavioral syndrome in rats

Ifenprodil--an antagonist at the modulatory site of the NMDA receptor complex sensitive to polyamines--intraperitoneally injected at doses of 3 or 10 mg/kg, dose dependently prevented the behavioral syndrome induced by intracerebroventricular administration of adrenocorticotropin (ACTH)-(1-24) in adult male rats (excessive grooming, stretching, yawning, penile erections). These data further support a role of the brain ornithine decarboxylase (ODC)-polyamine system in the ACTH-induced behavioral syndrome, and may suggest an involvement of excitatory amino acids.

Org 2766 prevents disruption of vestibular compensation by an NMDA receptor antagonist

The adrenocorticotrophic hormone fragment 4-9 (ACTH-(4-9)) analog, Org 2766 has been shown to accelerate vestibular compensation. However, N-methyl-D-aspartate (NMDA) receptor antagonists disrupt the recovery process. When Org 2766 was administered at a dose of 20 nmol/kg every 4 h for 52 h, it prevented the disruption of compensation usually produced by a single 5 mg/kg i.p. injection of the NMDA receptor antagonist 3-([+]-2-carboxy-piperazin-4yl)-propyl-1-phosphonic acid (CPP). NMDA receptor antagonists and ACTH-like peptides may produce their effects on compensation by acting directly or indirectly at the same receptor complex.

Functional recovery after brain infarction: plasticity and neural transplantation

In the past, little attention has been given to the role of brain plasticity for the long term functional outcome in experimental stroke although there is substantial evidence for plasticity in other experimental models of neurological disorders. Under clinical conditions, functional improvement occurs in most stroke survivors during the initial months after the ischemic incidence. Recent PET studies in stroke patients, investigated two months or later after stroke, indicate a considerable potential for functional plasticity in the adult human cerebral cortex. Research aimed at the identification of the mechanisms underlying functional recovery should be given high priority, particularly with regard to environmental factors and pharmacological interventions. Pilot experiments of environmental enrichment significantly improved the functional outcome of laboratory animals after brain infarction. Fetal neocortical tissue grafted into the infarcted area in adult rats received afferent fibres from the intact brain and responded to contralateral sensory stimulation with increased metabolic activity, indicating functional integration between neocortical grafts and host afferent systems. However, reciprocal connections from the graft to the host tissue were rare, and it remains to be shown whether grafting will be able to restore the complex cortical organization of the infarcted tissue.

Neuronal transmission of hippocampal CA1 neurones is modulated by corticotropin-like intermediate lobe peptide [CLIP; ACTH(18-39)]

The study was conducted to test whether CLIP [ACTH(18-39)] influences the neuronal transmission and the induction of long-term potentiation (LTP) in the hippocampus. The population spike was recorded in the hippocampal CA1 region of freely moving rats before and after intracerebroventricular (ICV) administration of CLIP in comparison to ACTH and saline (controls). After infusion of CLIP, the population spike amplitude (PSA) rose to about 200% of baseline values. After reaching this level, it was impossible to induce a further increase of PSA by tetanization. However, if the stimulus intensity was reduced to a new baseline level, electrically induced LTP could be observed. There were no significant changes after infusion of ACTH. Our results indicate that the ICV administration of CLIP leads to an enhancement of excitability in the hippocampal CA1 region, which might be independent of LTP.

An ACTH/MSH(4-9) analog counteracts the behavioral effects of a mineralocorticoid receptor antagonist

The ACTH/MSH(4-9) analog Org2766 has been demonstrated to counteract age-related behavioral and morphological parameters especially those related to hippocampal functioning. Hippocampal mineralocorticoid receptors (MRs) are known to decline in the senescent rat. This decrease can be also counteracted by a chronic treatment with an ACTH(4-9) analog. The apparent effect of the peptide on hippocampal functioning prompted us to study a possible interaction between ACTH and MRs at a behavioral level. A chronic treatment with the ACTH(4-9) analog prevented the behavioral alteration induced by a specific MR antagonist (RU28318; 100 ng/microliters, ICV) in the Morris water maze and a step-through avoidance task. A possible role for neuronal excitation, involving MR activation, in peptide-facilitated behavioral recovery as seen in lesion studies and aging is discussed.